Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.

Gordon, Kenneth B; Betts, Keith A; Sundaram, Murali; Signorovitch, James E; Li, Junlong; Xie, Meng; Wu, Eric Q; Okun, Martin M

Gordon, Kenneth B; Betts, Keith A; Sundaram, Murali; Signorovitch, James E; Li, Junlong; Xie, Meng; Wu, Eric Q; Okun, Martin M.

Afiliação

Gordon KB; Medical College of Wisconsin, Milwaukee, Wisconsin.
Betts KA; Analysis Group Inc, Boston, Massachusetts. Electronic address: keith.betts@analysisgroup.com.
Sundaram M; AbbVie Inc, North Chicago, Illinois.
Signorovitch JE; Analysis Group Inc, Boston, Massachusetts.
Li J; Analysis Group Inc, Boston, Massachusetts.
Xie M; Analysis Group Inc, Boston, Massachusetts.
Wu EQ; Analysis Group Inc, Boston, Massachusetts.
Okun MM; AbbVie Inc, North Chicago, Illinois; Fort HealthCare, Fort Atkinson, Wisconsin.

J Am Acad Dermatol ; 77(6): 1030-1037, 2017 Dec.

Article em En | MEDLINE | ID: mdl-28993007

Assuntos

Fármacos Dermatológicos/uso terapêutico; Metotrexato/uso terapêutico; Psoríase/tratamento farmacológico; Adulto; Feminino; Humanos; Masculino; Modelos Estatísticos; Prognóstico; Índice de Gravidade de Doença; Fatores de Tempo; Resultado do Tratamento

Palavras-chave

Psoriasis Area and Severity Index (PASI); discontinuation; methotrexate; moderate-to-severe psoriasis; prediction; response

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google